Vasopressin V1a receptor antagonist

This page covers all Vasopressin V1a receptor antagonist drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Vasopressin V1a receptor.

Targets

Vasopressin V1a receptor

Phase 3 pipeline (1)

• NPSP558 · Shire · Cardiovascular
  NPSP558 is a selective vasopressin V1a receptor antagonist that blocks vasopressin signaling to reduce aquaporin-2 water channel expression and increase urine output.

Patent intelligence

• vasopressin v1a receptor antagonist patent landscape — aggregated cliff calendar, attackable patents, originator estates